Brought to you by 
Hyupjin gets South Korean rights to Pharming's Ruconest
04 Apr 2012
Executive Summary
Private Korean pharmaco Hyupjin Corp. has licensed Korean marketing rights to Pharming Group NV’s (unmet medical needs) Ruconest (recombinant human C1 inhibitor) for acute attacks of hereditary angioedema (HAE).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com